Leerink Partnrs Issues Pessimistic Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings per share (EPS) estimates for Thermo Fisher Scientific in a research note issued to investors on Thursday, January 30th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $5.10 per share for the quarter, down from their previous forecast of $5.43. The consensus estimate for Thermo Fisher Scientific’s current full-year earnings is $23.29 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific’s Q1 2026 earnings at $5.67 EPS, Q2 2026 earnings at $6.28 EPS, Q3 2026 earnings at $6.33 EPS and Q4 2026 earnings at $7.45 EPS.

Several other equities research analysts have also recently commented on the company. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a research report on Friday. Bank of America decreased their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stifel Nicolaus dropped their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 target price for the company in a report on Friday, January 10th. Finally, Raymond James reiterated an “outperform” rating and issued a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $658.00.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock opened at $593.38 on Monday. The company has a market cap of $226.97 billion, a PE ratio of 35.90, a P/E/G ratio of 4.06 and a beta of 0.77. The business has a 50 day moving average of $541.37 and a 200 day moving average of $571.18. Thermo Fisher Scientific has a 52 week low of $493.30 and a 52 week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock repurchase program on Friday, November 15th that allows the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s board believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.44%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the completion of the sale, the chief executive officer now owns 33,608 shares of the company’s stock, valued at $18,757,296.96. This trade represents a 22.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders have sold 29,000 shares of company stock worth $15,859,540. Company insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legacy Investment Solutions LLC bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $26,000. Peterson Financial Group Inc. purchased a new position in shares of Thermo Fisher Scientific in the third quarter worth $27,000. Barrett & Company Inc. purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at $28,000. Missouri Trust & Investment Co purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth about $30,000. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.